Monthey Resident

Ninsun Biotech is a start-up based in Valais at BioArk. It operates in the field of oncology and is revolutionising the marking of cancer stem cells by offering, for the first time, a specific biomarker for several cancers, including lung, breast and colon. Current technologies rely on the use of a combination of non-specific markers, so Ninsun Biotech is breaking new ground with its patented technology, offering new prospects in terms of diagnosis, monitoring (companion tests) and, ultimately, individualised treatment for patients. Ninsun Biotech’s stem cell marking kits are also perfectly compatible with the current clinical chain of patient management.